Weekly shot may protect joints in hemophilia a
NCT ID NCT06941870
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a once-weekly infusion of efanesoctocog alfa can improve joint swelling (synovial hypertrophy) in people with moderate to severe hemophilia A. Researchers will use ultrasound to measure changes in joint health over 12 months. The trial enrolls 35 participants aged 12 and older who already have joint swelling.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Efanesoctocog alfa (a clotting factor medicine given intravenously once a week)
What this could lead to
If it works, this could show that weekly infusions of efanesoctocog alfa reduce joint damage and improve joint health in people with hemophilia A.
What could go wrong
This is a small, early-phase study with only 35 participants and no comparison group. It may not prove long-term benefit or work for everyone. Risks include infusion reactions and potential for developing inhibitors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FACTOR VIII DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Innovative Hematology, Inc.- Site Number : 8400006
RECRUITINGIndianapolis, Indiana, 46260, United States
-
Investigational Site Number : 1240003
RECRUITINGHamilton, Ontario, L8N 3Z5, Canada
-
Investigational Site Number : 1240004
RECRUITINGHamilton, Ontario, L8N 3Z5, Canada
-
Investigational Site Number : 1580001
RECRUITINGTaichung, 407, Taiwan
-
Investigational Site Number : 1580002
RECRUITINGTaipei, 114, Taiwan
-
Investigational Site Number : 1580003
RECRUITINGKaohsiung City, 80756, Taiwan
-
Investigational Site Number : 3920001
RECRUITINGSaitama, 330-8777, Japan
-
Investigational Site Number : 3920002
RECRUITINGHiroshima, 734-8551, Japan
-
Investigational Site Number : 3920003
RECRUITINGKawasaki, Kanagawa, 216-8511, Japan
-
Investigational Site Number : 3920004
RECRUITINGTokyo, 160-0023, Japan
-
Ohio State University Hospital East- Site Number : 8400001
RECRUITINGColumbus, Ohio, 43203-1779, United States
-
Orthopedic Institute for Children- Site Number : 8400009
RECRUITINGLos Angeles, California, 90007, United States
-
University of Iowa- Site Number : 8400004
RECRUITINGIowa City, Iowa, 52242, United States